Group 1 - On January 12, a total of 4 listed companies had their restricted shares unlocked, with a total market value of approximately 6.055 billion yuan [1] - The specific details of the restricted share unlocks are as follows: [1] - Zhongbai Group (Stock Code: 000759) had 7.3776 million shares unlocked under equity incentive restrictions [1] - Xianghe Industrial (Stock Code: 603500) had 554,000 shares unlocked under equity incentive restrictions [1] - Tianxin Pharmaceutical (Stock Code: 603235) had 263 million shares unlocked with an extended lock-up period [1] - Fulei New Materials (Stock Code: 605488) had 40,000 shares unlocked under equity incentive restrictions [1]

格隆汇1月9日丨祥和实业(603500.SH)公布，公司于近日从全国高新技术企业认定管理工作领导小组办 公室发布的《对浙江省认定机构2025年认定报备高新技术企业进行备案的公告》获悉，公司通过了高新 技术企业的重新认定，证书编号为GR202533007041，发证日期为2025年12月19日，有效期三年。本次 高新技术企业的认定系公司原高新技术企业证书有效期满后进行的重新认定。 ...

Group 1 - The core point of the article is that Xianghe Industrial has been re-certified as a national high-tech enterprise, allowing it to enjoy tax benefits for three consecutive years from 2025 to 2027 [2] Group 2 - The announcement was made on January 9, indicating the company's ongoing commitment to innovation and technology [2] - The re-certification is managed by the National High-tech Enterprise Recognition Management Work Leading Group Office [2] - This recognition is expected to provide significant financial advantages to the company through tax incentives [2]

Group 1 - China Shipbuilding Defense expects a net profit of 940 million to 1.12 billion yuan for 2025, an increase of 149.61% to 196.88% year-on-year [1] - China First Heavy Industries has only undertaken a small number of related accessory projects and has not generated revenue from them [2] - Huanyu Electronics plans to invest 30 million yuan in a private equity fund focused on AI and emerging industries [3] Group 2 - Zhixiang Jintai's GR1803 injection has been included in the priority review list by the National Medical Products Administration [4] - JianKai Technology's shareholder plans to reduce holdings by up to 3% of the company's shares [5] - Debon Holdings will continue to suspend trading from January 12 due to significant matters being planned [6] Group 3 - South Network Technology's shareholder intends to transfer 847.05 million shares, accounting for 1.50% of the total share capital [7] - Hengrui Medicine has received approval for clinical trials of four drugs [8] - Daotong Technology expects a net profit of 900 million to 930 million yuan for 2025, a year-on-year increase of 40.42% to 45.10% [10] Group 4 - Betta Pharmaceuticals has invested 50 million yuan to acquire a 20% stake in Hangzhou Zhixing Pharmaceutical [11] - Tianyu Biology reported a 10.38% year-on-year decline in cumulative sales revenue for 2025 [12] - Lifang Pharmaceutical's subsidiary has obtained a drug registration certificate for a pain relief product [13] Group 5 - R&F Properties reported a total sales revenue of approximately 14.21 billion yuan for 2025 [14] - Wanfu Biology expects a net profit decline of 87.71% to 91.81% for 2025 [15] - Dazhi expects a negative net profit for 2025 [16] Group 6 - Dongzhu Ecology is negotiating to terminate the acquisition of control over a satellite communication company [17] - Baotai has received a milestone payment of 10 million USD from Hikma Pharmaceuticals [18] - Huace Navigation expects a net profit of 670 million to 690 million yuan for 2025, a year-on-year increase of 14.84% to 18.27% [19] Group 7 - Shenzhen Gas reported a net profit decline of 3.45% for 2025 [20] - Baogang Co. plans to adjust the price of rare earth concentrate for Q1 2026 to 26,834 yuan per ton [21] - Jiuding Investment expects to report a loss for 2025 [22] Group 8 - Shanghai Pharmaceuticals has received a drug registration certificate for a treatment for myasthenia gravis [23] - Hualan Biological plans to acquire a 35% stake in Guangfeng Capsule [24] - Ruina Intelligent plans to invest 169.9 million yuan in a new R&D production base for heat pumps [25] Group 9 - Wantong Development expects to report a loss for 2025 [26] - Xianghe Industrial has completed the purchase of a 5% stake in Hezhixiang Technology [27] - Guangkang Biochemical received a warning letter from the Guangdong Securities Regulatory Commission [28] Group 10 - Xiaoming Co. reported a 37.07% year-on-year decline in chicken product sales revenue for December 2025 [29] - Luokai Co. won a procurement project from State Grid Fujian Power worth approximately 48.2 million yuan [30] - Minhe Co. reported a 65.22% year-on-year increase in the sales of commodity chick seedlings for December 2025 [31] Group 11 - Zhenghai Biological has obtained a registration certificate for calcium silicate bio-ceramic materials [32] - Three Gorges Energy reported a 5.99% year-on-year increase in cumulative total power generation for 2025 [33] - Huisheng Biological expects a net profit of 235 million to 271 million yuan for 2025 [34] Group 12 - Maihe Co. announced the release of the detention measures against its chairman [35] - Wandong's Alzheimer's project has been included in a national major special project for innovative drug development [36] - Kangxin New Materials plans to transfer forest land assets with a book value of 1.203 billion yuan [37] Group 13 - Greenland Holdings expects a net loss of 16 billion to 19 billion yuan for 2025 [39] - Zhongxin Fluorine Materials has obtained a pesticide production license [40]

证券代码：603500 证券简称：祥和实业 公告编号：2026-002 浙江天台祥和实业股份有限公司（以下简称"公司"）于 2025 年 11 月 18 日召开第四届董事会第十次会议，审议通过了《关于购买股权暨关联交易的议案》， 董事会同意公司以自有资金人民币 200 万元的价格购买鲍晓华女士持有的浙江 和之祥科技有限公司（以下简称"和之祥"）5%股权（对应和之祥注册资本金人 民币 200 万元已全部实缴）。本次交易完成后，公司将持有和之祥 5%股权。具 体内容详见公司于 2025 年 11 月 19 日在上海证券交易所网站（www.sse.com.cn） 披露的《浙江天台祥和实业股份有限公司关于购买股权暨关联交易的公告》（公 告编号：2025-059） 二、交易进展情况 截至本公告披露日，公司已按照《关于浙江和之祥科技有限公司之股权转让 协议》的约定向鲍晓华女士支付本次购买和之祥 5%股权的全部款项，完成本次 交易。 特此公告。 浙江天台祥和实业股份有限公司董事会 2026 年 1 月 10 日 浙江天台祥和实业股份有限公司 关于购买股权暨关联交易完成的公告 本公司董事会及全体董事保证本公告内容不存在任何虚 ...

浙江天台祥和实业股份有限公司（以下简称"公司"）于近日从全国高新 技术企业认定管理工作领导小组办公室发布的《对浙江省认定机构 2025 年认定 报备高新技术企业进行备案的公告》获悉，公司通过了高新技术企业的重新认 定，证书编号为 GR202533007041，发证日期为 2025 年 12 月 19 日，有效期三 年。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 证券代码：603500 证券简称：祥和实业 公告编号：2026-003 浙江天台祥和实业股份有限公司 关于公司通过高新技术企业重新认定的公告 本次高新技术企业的认定系公司原高新技术企业证书有效期满后进行的重 新认定。根据国家对高新技术企业税收优惠政策的相关规定，公司自本次通过 高新技术企业认定后连续三年（2025 年至 2027 年）可继续享受国家关于高新 技术企业的税收优惠政策。 特此公告。 浙江天台祥和实业股份有限公司董事会 2026 年 1 月 10 日 ...

祥和实业公告，公司已完成购买鲍晓华女士持有的浙江和之祥科技有限公司5%股权，交易价格为人民 币200万元。此次交易已于2025年11月18日经董事会审议通过，且相关款项已按协议约定支付完毕。交 易完成后，祥和实业将持有和之祥5%股权。 ...

Group 1 - The company Zhejiang Tiantai Xianghe Industrial Co., Ltd. has approved the purchase of a 5% equity stake in Zhejiang Hezhixiang Technology Co., Ltd. for a price of 2 million RMB [1] - The board of directors held a meeting on November 18, 2025, to discuss and approve the equity purchase and related transactions [1] - The transaction has been completed, with the necessary business registration and charter amendment procedures finalized at the Hangzhou Qiantang District Market Supervision Administration [1]

浙江天台祥和实业股份有限公司 关于购买股权暨关联交易的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、购买股权事项概述 浙江天台祥和实业股份有限公司（以下简称"公司"）于 2025 年 11 月 18 日召开第四届董事会第十次会议，审议通过了《关于购买股权暨关联交易的议案》， 董事会同意公司以自有资金人民币 200 万元的价格购买鲍晓华女士持有的浙江 和之祥科技有限公司（以下简称"和之祥"）5%股权（对应和之祥注册资本金人 民币 200 万元已全部实缴）。本次交易完成后，公司将持有和之祥 5%股权。具 体 内 容 详 见 公 司 于 2025 年 11 月 19 日 在 上 海 证 券 交 易 所 网 站 （http://www.sse.com.cn/）披露的《浙江天台祥和实业股份有限公司关于购买 股权暨关联交易的公告》（公告编号：2025-059） 二、交易进展情况 近日，和之祥在杭州市钱塘区市场监督管理局完成了本次股权交易相关工商 变更登记和章程备案登记等手续。 特此公告。 浙江天台祥和实业股份有限公司董事会 ...

Group 1 - The company has submitted a registration application for the issuance of convertible bonds to the China Securities Regulatory Commission (CSRC) after receiving approval from the Shanghai Stock Exchange Listing Review Committee [1] - The company encourages investors to pay attention to future announcements regarding the convertible bonds [1]